Notably, the antiproliferative effect on GSCs inhibited STAT3 activity and downstream GBM stemness regulators, including CD133, Sox2, Oct4, Nanog, ALDH1A1, and integrin α6. The gene discussed is SOX2; the disease is glioblastoma.